PH23240A - Difluoronucleosides as antiviral agents - Google Patents

Difluoronucleosides as antiviral agents

Info

Publication number
PH23240A
PH23240A PH34549A PH34549A PH23240A PH 23240 A PH23240 A PH 23240A PH 34549 A PH34549 A PH 34549A PH 34549 A PH34549 A PH 34549A PH 23240 A PH23240 A PH 23240A
Authority
PH
Philippines
Prior art keywords
difluoronucleosides
antiviral agents
antiviral
agents
Prior art date
Application number
PH34549A
Other languages
English (en)
Inventor
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23881409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH23240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH23240A publication Critical patent/PH23240A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
PH34549A 1983-03-10 1986-12-03 Difluoronucleosides as antiviral agents PH23240A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/473,883 US4526988A (en) 1983-03-10 1983-03-10 Difluoro antivirals and intermediate therefor

Publications (1)

Publication Number Publication Date
PH23240A true PH23240A (en) 1989-06-06

Family

ID=23881409

Family Applications (2)

Application Number Title Priority Date Filing Date
PH34549A PH23240A (en) 1983-03-10 1986-12-03 Difluoronucleosides as antiviral agents
PH35983A PH23593A (en) 1983-03-10 1987-10-26 Difluoronucleosides as antiviral agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH35983A PH23593A (en) 1983-03-10 1987-10-26 Difluoronucleosides as antiviral agents

Country Status (36)

Country Link
US (5) US4526988A (instruction)
EP (1) EP0122707B1 (instruction)
JP (2) JPS59175498A (instruction)
KR (1) KR860001283B1 (instruction)
AR (1) AR243533A1 (instruction)
AT (1) ATE29726T1 (instruction)
AU (1) AU565856B2 (instruction)
BG (1) BG40814A3 (instruction)
CA (2) CA1218647A (instruction)
CS (1) CS246075B2 (instruction)
CY (1) CY1489A (instruction)
DD (1) DD216468A5 (instruction)
DE (2) DE3466224D1 (instruction)
DK (2) DK162529C (instruction)
ES (1) ES8602840A1 (instruction)
FI (1) FI77870C (instruction)
GB (2) GB2136425B (instruction)
GR (1) GR81845B (instruction)
HK (1) HK44989A (instruction)
HU (1) HU193893B (instruction)
IE (1) IE57071B1 (instruction)
IL (2) IL71143A (instruction)
KE (1) KE3874A (instruction)
LU (1) LU88791I2 (instruction)
MX (1) MX9203246A (instruction)
MY (1) MY102025A (instruction)
NL (1) NL950018I2 (instruction)
NZ (1) NZ207358A (instruction)
PH (2) PH23240A (instruction)
PL (1) PL142437B1 (instruction)
PT (1) PT78181B (instruction)
RO (1) RO89963A (instruction)
SG (1) SG21889G (instruction)
SU (1) SU1442076A3 (instruction)
UA (1) UA5955A1 (instruction)
ZA (1) ZA841605B (instruction)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
PT86377B (pt) * 1986-12-24 1990-11-20 Lilly Co Eli Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
EP0277599A3 (en) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Fluorine containing cyclopentane derivatives and processes for their production
CA1340645C (en) * 1987-04-17 1999-07-13 Victor E. Marquez Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
CA1324128C (en) 1987-08-28 1993-11-09 Ta-Sen Chou 2', 2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
EP0364559B1 (en) * 1988-03-16 1995-09-20 The Scripps Research Institute Substituted adenine derivatives useful as therapeutic agents
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
CA2012129A1 (en) * 1989-03-20 1990-09-20 Ramakrishnan Nagarajan Recovery of difluoro sugar
US4954623A (en) * 1989-03-20 1990-09-04 Eli Lilly And Company Recovery of difluoro sugar
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5401861A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5252756A (en) * 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
US5256798A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5256797A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
JPH0673086A (ja) * 1992-06-22 1994-03-15 Eli Lilly & Co 立体選択的な陰イオングリコシル化法
JP3291071B2 (ja) * 1992-06-22 2002-06-10 イーライ・リリー・アンド・カンパニー アルファ−アノマーに富む１−ハロ−２−デオキシ−２，２−ジフルオロ−ｄ−リボフラノシル誘導体の製造方法
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5428176A (en) * 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
CA2171518A1 (en) * 1995-03-24 1996-09-25 Douglas Patton Kjell Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
US5633367A (en) * 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
EP0779275A2 (en) 1995-12-13 1997-06-18 Eli Lilly And Company Alpha, Alpha - Difluoro-beta -hydroxy thiol esters and their synthesis
US5808020A (en) * 1996-08-12 1998-09-15 Associated Universities, Inc. Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
US6013790A (en) * 1996-09-25 2000-01-11 Board Of Regents University Of Nebraska-Lincoln Heavily fluorinated sugar analogs
AU6473098A (en) * 1997-03-24 1998-10-20 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
PT1058686E (pt) * 1998-02-25 2007-01-31 Raymond F Schinazi 2'-fluoronucleósidos
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002365256A1 (en) * 2001-10-25 2003-07-30 Eli Lilly And Company Gemcitabine in the treatment of smallpox
US7176237B2 (en) * 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1480982A4 (en) * 2002-02-14 2007-08-01 Pharmasset Inc MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
WO2004105732A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
PT1633766T (pt) * 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
WO2005044788A1 (ja) * 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
BRPI0507463A (pt) 2004-02-06 2007-07-10 Threshold Pharmaceuticals Inc uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine
EP1732947B1 (en) * 2004-03-05 2011-04-27 Vegenics Pty Ltd Growth factor binding constructs materials and methods
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
AU2005267051B2 (en) * 2004-07-21 2011-07-14 Gilead Sciences, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
US7858761B2 (en) * 2004-07-29 2010-12-28 Hanmi Pharm. Co., Ltd 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof
WO2006015346A1 (en) * 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
CA2580457C (en) * 2004-09-14 2014-11-04 Pharmasset, Inc. Preparation of 2'­fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
WO2006063105A1 (en) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
SI1831237T1 (sl) * 2004-12-17 2009-02-28 Lilly Co Eli Amidno predzdravilo gemcitabina, zmesi in njihovauporaba
KR101345002B1 (ko) 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
ES2341663T3 (es) * 2005-03-04 2010-06-24 Fresenius Kabi Oncology Limited Intermedio y procedimiento para preparar 2'-desoxi-2',2'-difluoro-d-ribofuranosil nucleosidos enriquecidos en el anomero beta.
WO2006119347A1 (en) * 2005-05-02 2006-11-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
JP5091126B2 (ja) * 2005-06-03 2012-12-05 シノファーム タイワン，リミテッド α−アノマーが濃厚な２−デオキシ−２，２−ジフロロ−Ｄ−リボフラノシルスルホネートの製造方法およびβヌクレオシドを製造するためのその使用
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
NZ565654A (en) 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
AT502221A1 (de) * 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007015257A2 (en) * 2005-08-04 2007-02-08 Hetero Drugs Limited A process for the preparation of gemcitabine using novel intermediates
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
EP1940859A1 (en) 2005-10-28 2008-07-09 Arch Pharmalabs Limited An improved process for preparation of gemcitabine hydrochloride
WO2007052849A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
CA2631951A1 (en) * 2005-12-14 2007-06-21 Dong-A Pharm. Co., Ltd. A manufacturing process of 2',2'-difluoronucleoside and intermediate
US20090069557A1 (en) * 2006-02-06 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of gemcitabine
US20070191598A1 (en) * 2006-02-07 2007-08-16 Chemagis Ltd. Process for Preparing Gemcitabine and Associated Intermediates
US20070249823A1 (en) * 2006-04-20 2007-10-25 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
KR100741310B1 (ko) * 2006-08-01 2007-08-01 (주) 유일팜테크 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
EP2065372B1 (en) * 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
HRP20120683T1 (hr) 2006-10-27 2012-09-30 Genentech Protutijela i imunokonjugati te njihove uporabe
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
JP2010510243A (ja) * 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
KR101445892B1 (ko) * 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
JP5349342B2 (ja) * 2007-03-23 2013-11-20 ドンウ シンテック カンパニー リミテッド ２’−デオキシ−２’，２’−ジフルオロシチジンの製造方法
CN101024667B (zh) * 2007-03-30 2011-01-26 湖北益泰药业有限公司 盐酸吉西他宾的合成方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
CN100475832C (zh) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
CA2693623A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US20090069354A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
JP4253357B1 (ja) 2007-09-27 2009-04-08 株式会社湯山製作所 手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
BRPI0817364A2 (pt) * 2007-11-06 2019-09-24 Pharmaessentia Corp processo de preparação de um composto de beta-nucleosídeo e composto
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
BRPI0820298A8 (pt) 2007-11-09 2018-05-08 Affitech Res As composições e métodos de anticorpos anti-vegf
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009089545A1 (en) 2008-01-11 2009-07-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
EA020467B1 (ru) 2008-04-18 2014-11-28 Ритэ Фамэсутикл, Инк. Соединения, обладающие противовоспалительной активностью, и фармацевтическая композиция на их основе
TW201004627A (en) * 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
ES2613964T3 (es) * 2008-04-18 2017-05-29 Reata Pharmaceuticals, Inc. Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17
HRP20182060T1 (hr) 2008-04-18 2019-03-22 Reata Pharmaceuticals, Inc. Antioksidantni modulatori upale: derivati oleanolne kiseline s amino i drugim modifikacijama na c-17
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2303906B1 (en) * 2008-06-12 2016-06-08 ScinoPharm Taiwan, Ltd. Crystalline polymorphs of gemcitabine base
ES2449396T3 (es) * 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8329666B2 (en) * 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
ES2593088T3 (es) * 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
US20120129799A1 (en) 2009-07-31 2012-05-24 Astron Research Limited stable composition of ready-to-use gemcitabine injection
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US20130065883A1 (en) 2010-02-18 2013-03-14 Centro Nacional de Investigaceiones Oncologicas (CNIO) Triazolo [4, 5- B] Pyridin Derivatives
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
PH12013500629A1 (en) 2010-09-22 2019-10-11 Alios Biopharma Inc Substituted nucleotide analogs
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN102153602B (zh) * 2011-02-24 2013-11-06 中国农业大学 呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
CN102153601A (zh) * 2011-02-26 2011-08-17 湖南欧亚生物有限公司 一种高选择性的制备盐酸吉西他滨以及其中间体的方法
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
SG194051A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and vemurafenib, and methods of use
TWI462931B (zh) 2011-04-07 2014-12-01 Pharmaessentia Corp β－核苷的合成技術
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PH12013502141A1 (en) 2011-04-13 2014-01-06 Merck Sharp & Dohme 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696679B1 (en) 2011-04-13 2017-08-02 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102453064B (zh) * 2011-06-30 2014-07-09 江苏豪森药业股份有限公司 制备吉西他滨盐酸盐的方法
EP2731434A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
CN103857403B (zh) 2011-10-03 2019-04-12 Mx佐剂股份公司 纳米颗粒、制备方法以及其应用
CN102417533A (zh) * 2011-10-28 2012-04-18 江苏正大清江制药有限公司 盐酸吉西他滨的合成方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NO2755614T3 (instruction) 2012-01-03 2018-03-31
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
EA031301B1 (ru) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-аминокислотные химические соединения для лечения заболеваний печени
KR101689946B1 (ko) 2012-06-08 2016-12-26 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
KR102090849B1 (ko) 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 공유 결합된 항원-항체 접합체
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
WO2014058801A1 (en) 2012-10-08 2014-04-17 Idenix Pharmaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
ES2582339T3 (es) * 2013-07-10 2016-09-12 Asteriapharma Gmbh Composiciones que comprenden oligómeros de gemcitabina para su uso en terapia
WO2015013448A1 (en) 2013-07-26 2015-01-29 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
CN105517540B (zh) 2013-08-27 2019-08-23 吉利德制药有限责任公司 两种抗病毒化合物的复方制剂
SG11201602614XA (en) 2013-10-29 2016-05-30 Otsuka Pharma Co Ltd Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
US9937261B2 (en) 2014-06-09 2018-04-10 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
CN106687476B (zh) 2014-06-26 2020-11-13 豪夫迈·罗氏有限公司 抗brdu抗体及使用方法
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
WO2016138026A1 (en) * 2015-02-25 2016-09-01 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
KR20250020678A (ko) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
ES2887426T3 (es) 2015-08-20 2021-12-22 Eisai R&D Man Co Ltd Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
EA037248B1 (ru) * 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
MA43405B1 (fr) 2015-12-11 2021-11-30 NuCana plc Syntheses diastereoselectives de dérivés phosphates et du promedicament de gemcitabine nuc-1031
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
EP3541404A1 (en) 2016-11-21 2019-09-25 Bexion Pharmaceuticals, Inc. A combination therapy including sapc-dops for the treatment of pancreatic cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
JP2020530003A (ja) 2017-08-07 2020-10-15 アムジェン インコーポレイテッド 抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
EP3826667B1 (en) 2017-09-18 2024-04-17 The Regents of the University of California Claudin6 antibodies and methods of treating cancer
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
MX2020007393A (es) 2018-01-10 2020-11-24 Nucorion Pharmaceuticals Inc Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal.
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
US12171746B2 (en) 2019-01-11 2024-12-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
SG11202109986TA (en) 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
US20220177583A1 (en) 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
KR20220035143A (ko) 2019-07-17 2022-03-21 누코리온 파마슈티컬스, 인코포레이티드. 사이클릭 디옥시리보뉴클레오티드 화합물
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4143199A4 (en) 2020-04-21 2024-07-03 Ligand Pharmaceuticals, Inc. NUCLEOTIDE PRODRUG COMPOUNDS
WO2025019361A1 (en) 2023-07-14 2025-01-23 Modulation Therapeutics, Inc. Scd1 inhibitors for treating hematolymphoid neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
FR1362039A (fr) * 1963-04-17 1964-05-29 Ct D Etudes Experimentales Et Nouveau procédé de préparation du semi-aldéhyde succinique
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents

Also Published As

Publication number Publication date
JPS59175498A (ja) 1984-10-04
AU2537484A (en) 1984-09-13
SG21889G (en) 1989-07-14
EP0122707B1 (en) 1987-09-16
KR860001283B1 (ko) 1986-09-05
CA1223869A (en) 1987-07-07
GB2136425A (en) 1984-09-19
US4692434A (en) 1987-09-08
ZA841605B (en) 1985-10-30
FI840890L (fi) 1984-09-11
GB8405805D0 (en) 1984-04-11
FI77870C (fi) 1989-05-10
IE57071B1 (en) 1992-04-22
UA5955A1 (uk) 1994-12-29
DK190590A (da) 1990-08-10
US4526988A (en) 1985-07-02
MY102025A (en) 1992-02-29
KR840007883A (ko) 1984-12-11
PL246601A1 (en) 1985-08-13
CS246075B2 (en) 1986-10-16
JPH06102655B2 (ja) 1994-12-14
DK190590D0 (da) 1990-08-10
IL80463A (en) 1988-07-31
DK162529C (da) 1992-03-30
DK114484A (da) 1984-09-11
DK170647B1 (da) 1995-11-20
HU193893B (en) 1987-12-28
SU1442076A3 (ru) 1988-11-30
HK44989A (en) 1989-06-09
JPH069602A (ja) 1994-01-18
DE19675003I2 (de) 2003-05-22
BG40814A3 (bg) 1987-02-16
LU88791I2 (fr) 1996-11-05
MX9203246A (es) 1992-07-31
IE840584L (en) 1984-09-10
GB8610648D0 (en) 1986-06-04
US4808614A (en) 1989-02-28
JPH0542438B2 (instruction) 1993-06-28
PH23593A (en) 1989-09-11
PT78181B (en) 1986-08-05
EP0122707A1 (en) 1984-10-24
IL80463A0 (en) 1987-01-30
IL71143A0 (en) 1984-06-29
CY1489A (en) 1989-12-08
DK114484D0 (da) 1984-02-28
KE3874A (en) 1989-06-30
FI840890A0 (fi) 1984-03-06
FI77870B (fi) 1989-01-31
GB2136425B (en) 1987-05-13
ES530364A0 (es) 1985-12-01
US5118820A (en) 1992-06-02
RO89963A (ro) 1986-09-30
CA1218647A (en) 1987-03-03
PL142437B1 (en) 1987-10-31
NL950018I2 (nl) 1997-03-03
DK162529B (da) 1991-11-11
NZ207358A (en) 1987-03-06
IL71143A (en) 1988-07-31
GB2172287A (en) 1986-09-17
ES8602840A1 (es) 1985-12-01
ATE29726T1 (de) 1987-10-15
AR243533A1 (es) 1993-08-31
US5015743A (en) 1991-05-14
DE3466224D1 (en) 1987-10-22
PT78181A (en) 1984-04-01
GB2172287B (en) 1987-05-20
AU565856B2 (en) 1987-10-01
GR81845B (instruction) 1984-12-12
NL950018I1 (instruction) 1995-11-01
DD216468A5 (de) 1984-12-12

Similar Documents

Publication Publication Date Title
PH23593A (en) Difluoronucleosides as antiviral agents
GB2150570B (en) Novel antiviral agents
GR80237B (en) Novel oxazolines as antiviral agents
PH19050A (en) Pest-combating agents
GB8320308D0 (en) Antiviral combinations
GB2119650B (en) Antiviral isothiosemicarbazones
ZA843152B (en) Antiviral agents
ZA837814B (en) Antiviral agent
DE3468322D1 (en) Antiviral agent
ZA844744B (en) Antiviral agents
CS709284A2 (en) Zpusob pripravy novych kondenzovanych derivatu as triazinu
DE3463443D1 (en) Hand piece
PH17379A (en) 4-arylaliphatic-isoxazoles useful as antiviral agents
GB8320309D0 (en) Antiviral compounds
GB8327824D0 (en) Mycostatic agents
GB8303406D0 (en) Smoke-flavouring agents
CS746585A2 (en) Zpusob pripravy novych kondezovanych derivatu as triazinu
CS669383A1 (en) Zpusob fermentacni vyroby thiaminasy i thiam
GB8330251D0 (en) Trestle
CS496083A1 (en) Skrabakova nadoba s posuvnymi sklopnymi dvirky
CS1028783A1 (en) Zapojenie generatora riadiacich impulzov s kompenzaciou zmeny napajacieho napaetia
CS265883A1 (en) Zpusob mechanickeho obrabeni s ohrevem odrezavane vrstvy
CS326284A2 (en) Zpusob vyroby aminu s ldialkoxythiofosforyl pthioglykolove kyseliny
CS331983A1 (en) Tenkostenne potrubie s ochrannou vrstvou
CS339383A1 (en) Armatura s pruzinovym pohonem